Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

Thrombectomy Using Pulsed Aspiration for Reperfusion of Brain Occlusions

NCT06029491 · tracked via the Priya Life Science USA tracker
Sponsor
RapidPulse, Inc
Phase
Not applicable
Started
2025-03-27
Last updated
2026-10-21

Condition(s) studied

Acute Ischemic Stroke

Investigational drug(s) / intervention(s)

RapidPulseTM Aspiration System

RapidPulseTM Aspiration System: The RapidPulseTM Aspiration System is designed to remove occlusive thrombus from the occluded cerebral vasculature using precisely pulsed aspiration. The system is comprised of the multi-use, non-sterile RapidPulseTM Aspiration Pump, the single use, sterile RapidPulseTM Tube set, the single use, non-sterile RapidPulseTM Collection Canister and the single use, sterile RapidPulseTM 071 Catheter.

Study summary

The goal of this clinical trials is to demonstrate the safety and effectiveness for the RapidPulseTM Aspiration System in patients experiencing acute ischemic stroke within 8 hours of symptom onset or last seen normal. Subjects will undergo mechanical thrombectomy (a procedure to remove a clot in the brain which is preventing blood flow), with the RapidPulseTM Aspiration System. Participation in the trial is for 90 days.

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: * Age 18 to 85 years * Clinical diagnosis of acute ischemic stroke with NIH Stroke Scale (NIHSS) score ≥ 6 * Able to be treated within 8 hours of symptom onset or last known normal (LKN) * Able to be treated within 120 minutes from the time of the qualifying baseline CT/MR image * Pre-morbid Modified Rankin Scale (mRS) score 0-1 * Angiographic confirmation of large vessel occlusion (LVO) in the anterior (intracranial ICA or MCA M1 or M2 segments) or posterior circulation (vertebral or basilar arteries) as confirmed by digital subtraction angiography (DSA) irrespective of IV thrombolysis administration * Candidate to receive treatment with ADAPT technique (Direct Aspiration First-Pass Technique) Exclusion Criteria: * Intracranial Hemorrhage (ICH) * Significant mass effect and/or midline shift * Alberta Stroke Program Early CT Score (ASPECTS) \<6 or (PC-ASPECTS \<8 on CT angiography source images or DWI MRI for posterior circulation stroke) * Intracranial Atherosclerotic Disease (ICAD) * Multiple or tandem occlusions * Life expectancy less than 6 months

Primary outcome measure(s)

  • Rate of perfusion success using only the study device. — Intra-procedural
    The proportion of patients who achieve mTICI ≥ 2b within a maximum of 3 passes where only aspiration with the Study Device was used without rescue, as assessed by an independent Imaging Core Lab.
  • Rate of symptomatic intracranial hemorrhage (sICH) — Post-procedural (24 hours post-thrombectomy)
    The proportion of patients with symptomatic ICH (sICH) at 24 hours post-thrombectomy

Trial sites (30)

FacilityCityRegionStatus
Providence Saint John's Medical Foundation Torrance California Recruiting
Yale University New Haven Connecticut Recruiting
Baptist Health Research Institute Jacksonville Florida Recruiting
University of South Florida Tampa Florida Recruiting
Emory University at Grady Atlanta Georgia Recruiting
Rush University Medical Center Chicago Illinois Recruiting
Advocate Aurora Research Institute Park Ridge Illinois Recruiting
Indiana University Health Indianapolis Indiana Not Yet Recruiting
State University of Iowa Iowa City Iowa Recruiting
Washington University St Louis Missouri Recruiting
Cooper Health System Camden New Jersey Not Yet Recruiting
State University of New York at Buffalo Buffalo New York Recruiting
Icahn School of Medicine at Mount Sinai New York New York Recruiting
UPMC Pittsburgh Pennsylvania Active Not Recruiting
Prisma Health Greenville South Carolina Withdrawn
Semmes Murphey Foundation - Baptist Memorial Hospital Memphis Tennessee Recruiting
Vanderbilt University Medical Center Nashville Tennessee Withdrawn
Valley Baptist Medical Center - Harlingen Harlingen Texas Recruiting
Centre Hospitalier Universitaire de Bordeaux Bordeaux France Not Yet Recruiting
Centre Hospitalier Universitaire de Montpellier Montpellier France Not Yet Recruiting
Centre Hospitalier Universitaire de Toulouse Toulouse France Not Yet Recruiting
Hospital General Universitario Dr. Balmis Alicante Spain Recruiting
Hospital Universitari Germans Trias i Pujol Badalona Spain Recruiting
Hospital Universitari Vall d' Hebron Barcelona Spain Recruiting
Hospital Universitari de Bellvitge Barcelona Spain Recruiting
Hospital Universitari de Girona Dr. Josep Trueta Girona Spain Not Yet Recruiting
Hospital Universitario de la Princesa Madrid Spain Recruiting
Hospital Universitario 12 de Octubre Madrid Spain Recruiting
Hospital Universitario La Paz Madrid Spain Recruiting
Istanbul Aydan Universitesi VM Medical Park Florya Hastanesi Istanbul Turkey (Türkiye) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06029491 on ClinicalTrials.gov ↗ ← All trials in the USA